LSBio
IHC-plus™ c-Met Antibody (Cytoplasmic Domain)

Anti-c-Met antibody IHC of human uterus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody concentration 10 ug/ml.

IHC-plus™ c-Met Antibody (Cytoplasmic Domain)

Primary AntibodyLSBio Guarantee
Antibody:Mouse Monoclonal
Applications:Immunohistochemistry (general), Immunohistochemistry, Frozen, Immunohistochemistry, Paraffin
Reactivity:Human
Format:Liquid
See all c-Met antibodies →
$628.00each
Catalog Number: LS-B2812-50

For bulk orders or custom formulations:

Request a Quote

Overview

Description
C-Met antibody LS-B2812 is an unconjugated mouse monoclonal antibody to human c-Met (Cytoplasmic Domain). Validated for IHC. Tested on 20 paraffin-embedded human tissues. Cited in 3 publications.
Application
IHC, IHC-F, IHC-P
Reactivity
Hu
Intended Use
Research Use Only
Guarantees
This product carries the LSBio 100% Guarantee.
Category
Antibodies > Primary Antibodies > Monoclonal Antibodies
Alternative Names
AUTS9 | C-Met | HGF/SF receptor | HGFR | MET | Met kinase | Proto-oncogene c-Met | Scatter factor receptor | SF receptor | HGF receptor | RCCP2 | Tyrosine-protein kinase Met
Recommended Dilution: IHC-F
1:50
Recommended Dilution: IHC-P
10 µg/ml
UniProt Number
P08581
SwissProt
P08581

Target

Target
c-Met
Antigen Species
Human
Specificity
Recognizes c-Met.
Epitope
Recognizes c-Met.
Gene Name
MET

Antibody

Host Species
Mouse
Clonality
Monoclonal
Origin Species
Human

Immunogen

Immunogen
Synthetic peptide derived from cytoplasmic domain of human c-Met protein
Immunogen Type
Synthetic Peptide (Linear)

Format

Conjugate/Label
Unconjugated
Format
Liquid
Formulation
PBS, pH 7.4, 0.09% Sodium Azide, 1% BSA
Concentration
1.14 mg/mL
Volume
50 Microliter
Animal Free
No
Carrier-Free
No
Preservative
Yes
Purification Method
Other

Storage & Handling

Storage Conditions
Short term: store at 4°C. Long term: aliquot and store at -20°C. Avoid freeze-thaw cycles.
Recommended Storage Buffer
PBS

MET Gene Status in Malignant Mesothelioma Using Fluorescent In Situ Hybridization. Varesano S, Salvi S, Boccardo S, Ravetti JL, Pistillo MP, Canessa PA, Ferro P, Fedeli F, Roncella S. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 February;11:e28-e30.

PubMed: 26811229


A Case of Atypical Carcinoid: Harboring Variant 3a/b EML4-ALK Rearrangement. Fukuizumi A, Akagi K, Sakai H. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015 October;10:e104-e106.

PubMed: 26398829


EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies. Sandra Salvi, Serena Varesano, Simona Boccardo, Jean Louis Ravetti, Pier Aldo Canessa, Maria Pia Pistillo, Paola Ferro, Franco Fedeli, Silvio Roncella. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2016 Jun;11:e78-80.

PubMed: 27211582

Request SDS/MSDS

To request an SDS/MSDS form for this product, please contact our Technical Support department at: technical@vectorlabs.com.